Ozempic Gastroparesis Causation: Statute of Limitations for Ozempic in Washington

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

Legacy of Medical Ethics in Health Information

Medical Ethics has long served as a public resource for general health and science information, providing clinicians and scholars with balanced reviews on safety and ethical practice. This legacy of accessible, neutral guidance now extends to emerging concerns about pharmaceutical exposures in community and occupational settings. As new prescription therapies enter widespread use, questions naturally arise about potential long-term health effects for those who handle or are exposed to these substances. One such therapy is Ozempic, a medication increasingly prescribed for metabolic conditions. Reports of gastrointestinal complications, including gastroparesis, have prompted careful review of exposure risks. For individuals in Washington who may have experienced such effects, understanding the applicable statute of limitations is critical for evaluating any legal recourse. This transition from general health education to specific exposure inquiry reflects the evolving role of medical ethics in addressing real-world safety questions. The focus remains on factual, evidence-informed discussion without advancing mechanistic claims, ensuring that the conversation stays grounded in public health principles while acknowledging the need for timely legal awareness.

Ozempic and Gastrointestinal Adverse Reactions: Clinical Evidence

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its prescribing information documents a range of gastrointestinal adverse reactions, which are among the most commonly reported side effects. Gastroparesis, a condition characterized by delayed gastric emptying without mechanical obstruction, is not explicitly listed as a labeled adverse reaction in the Ozempic prescribing information. However, the clinical presentation of gastroparesis—including nausea, vomiting, abdominal pain, and early satiety—overlaps significantly with the gastrointestinal adverse reactions that are reported in clinical trials for Ozempic. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: 15.3% for placebo, 32.7% for Ozempic 0.5 mg, and 36.4% for Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) versus Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients with type 2 diabetes mellitus in placebo-controlled trials include nausea (placebo 6.1%, Ozempic 0.5 mg 15.8%, Ozempic 1 mg 20.3%), vomiting (placebo 2.3%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 9.2%), diarrhea (placebo 1.9%, Ozempic 0.5 mg 8.5%, Ozempic 1 mg 8.8%), abdominal pain (placebo 4.6%, Ozempic 0.5 mg 7.3%, Ozempic 1 mg 5.7%), and constipation (placebo 1.5%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 3.1%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In the pool of placebo- and active-controlled trials and in the 2-year cardiovascular outcomes trial, the types and frequency of common adverse reactions, excluding hypoglycemia, were similar to those listed (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a clinical trial with 959 patients treated with Ozempic 1 mg or Ozempic 2 mg once weekly as add-on to metformin with or without sulfonylurea treatment for 40 weeks, no new safety signals were identified (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Mechanistic Pathways and Causation Considerations

The mechanistic pathways linking Ozempic to gastroparesis are grounded in the pharmacology of GLP-1 receptor agonists. GLP-1 receptor agonists slow gastric emptying, which is a known pharmacodynamic effect. This delay in gastric emptying can lead to symptoms that mimic gastroparesis, such as nausea, vomiting, and abdominal discomfort. In patients with pre-existing gastroparesis or those who develop severe symptoms, the drug may exacerbate or unmask the condition. The prescribing information does not specifically warn about gastroparesis, but it does include a warning about hypersensitivity reactions, including anaphylaxis and angioedema, which have been reported with other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This indicates that the drug class can cause serious adverse events, though gastroparesis is not among those explicitly listed. From a causation-focused clinical interpretation, patients who develop symptoms consistent with gastroparesis—such as persistent nausea, vomiting, abdominal pain, and early satiety—after starting Ozempic should be evaluated for the condition. The timeline between exposure and documented health outcomes is critical. In clinical trials, gastrointestinal adverse reactions occurred most frequently during dose escalation, suggesting that symptoms may emerge early in treatment. However, the duration of symptoms and their persistence after dose adjustment or discontinuation are important factors in establishing a causal link. The prescribing information notes that the majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation, but it does not provide specific data on the duration or resolution of these symptoms after stopping the drug. In the context of safety communication, the FDA has not issued a specific warning about Ozempic and gastroparesis. However, the high incidence of gastrointestinal adverse reactions—particularly nausea and vomiting—raises concerns about the potential for gastroparesis in susceptible individuals. Patients with diabetes, who are already at increased risk for gastroparesis due to autonomic neuropathy, may be particularly vulnerable. The prescribing information does not contraindicate Ozempic in patients with gastroparesis, but clinicians should exercise caution when prescribing it to patients with a history of severe gastrointestinal disease.

Statute of Limitations for Ozempic Claims in Washington

For patients in Washington considering legal action regarding Ozempic and gastroparesis, the statute of limitations is a critical factor. In Washington, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally three years from the date of injury or from when the injury was discovered or should have been discovered. This means that patients who developed gastroparesis after using Ozempic must medical context within three years of recognizing the link between the drug and their condition. Given that Ozempic was approved by the FDA in 2017, and the first reports of gastrointestinal adverse reactions were documented in clinical trials, patients who began treatment early may have a limited window to purmedical context legal action. It is essential for affected individuals to consult with a legal professional to determine the specific deadlines applicable to their case. In summary, while Ozempic is not explicitly linked to gastroparesis in its prescribing information, the drug's known effects on gastric emptying and the high incidence of gastrointestinal adverse reactions provide a plausible mechanistic pathway. Patients who experience persistent gastrointestinal symptoms after starting Ozempic should seek medical evaluation and consider the potential for gastroparesis. For those in Washington, the statute of limitations for filing a claim is three years from the date of discovery of the injury, making timely action important.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic-related gastroparesis claims in Washington?

In Washington, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally three years from the date of injury or from when the injury was discovered or should have been discovered. Patients who developed gastroparesis after using Ozempic must medical context within three years of recognizing the link between the drug and their condition.

Is gastroparesis listed as a side effect of Ozempic?

Gastroparesis is not explicitly listed as a labeled adverse reaction in the Ozempic prescribing information. However, the drug's known effects on gastric emptying and the high incidence of gastrointestinal adverse reactions such as nausea, vomiting, and abdominal pain provide a plausible mechanistic pathway for gastroparesis in susceptible individuals.

Does submitting information create an medical context-client relationship?

No. Submission requests an initial records screening only and does not create an medical context-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.